|
JPS5892644A
(ja)
|
1981-11-26 |
1983-06-02 |
Taiho Yakuhin Kogyo Kk |
新規なニトロ安息香酸アミド誘導体およびそれを含有する放射線増感剤
|
|
US4694778A
(en)
|
1984-05-04 |
1987-09-22 |
Anicon, Inc. |
Chemical vapor deposition wafer boat
|
|
US5185444A
(en)
|
1985-03-15 |
1993-02-09 |
Anti-Gene Deveopment Group |
Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
|
|
WO1986005519A1
(en)
|
1985-03-15 |
1986-09-25 |
James Summerton |
Polynucleotide assay reagent and method
|
|
US4866132A
(en)
|
1986-04-17 |
1989-09-12 |
The Research Foundation Of State University Of New York |
Novel radiopaque barium polymer complexes, compositions of matter and articles prepared therefrom
|
|
US5624925A
(en)
|
1986-09-25 |
1997-04-29 |
Sri International |
1,2,4-benzotriazine oxides as radiosensitizers and selective cytotoxic agents
|
|
US4921963A
(en)
|
1987-04-13 |
1990-05-01 |
British Columbia Cancer Foundation |
Platinum complexes with one radiosensitizing ligand
|
|
JPH0819111B2
(ja)
|
1987-10-22 |
1996-02-28 |
ポーラ化成工業株式会社 |
２―ニトロイミダゾール誘導体及びこれを有効成分とする放射線増感剤
|
|
US4828971A
(en)
|
1988-03-24 |
1989-05-09 |
Eastman Kodak Company |
Thermally processable element comprising a backing layer
|
|
CA1251835A
(en)
|
1988-04-05 |
1989-03-28 |
Wai-Cheung Tang |
Dielectric image-resonator multiplexer
|
|
US5256334A
(en)
|
1988-09-08 |
1993-10-26 |
The Research Foundation Of The State University Of New York |
Homogeneous radiopaque polymer-organobismuth composites
|
|
WO1991004753A1
(en)
|
1989-10-02 |
1991-04-18 |
Cetus Corporation |
Conjugates of antisense oligonucleotides and therapeutic uses thereof
|
|
US5208020A
(en)
|
1989-10-25 |
1993-05-04 |
Immunogen Inc. |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
|
WO1992007065A1
(en)
|
1990-10-12 |
1992-04-30 |
MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. |
Modified ribozymes
|
|
DE4216134A1
(de)
|
1991-06-20 |
1992-12-24 |
Europ Lab Molekularbiolog |
Synthetische katalytische oligonukleotidstrukturen
|
|
CA2123307A1
(en)
|
1991-11-26 |
1993-06-10 |
Phillip M. Friden |
Process for the preparation of transferrin receptor specific antibody-neuro-pharmaceutical or diagnostic agent conjugates
|
|
US5652094A
(en)
|
1992-01-31 |
1997-07-29 |
University Of Montreal |
Nucleozymes
|
|
WO1994004147A1
(en)
|
1992-08-17 |
1994-03-03 |
Quadra Logic Technologies, Inc. |
Method for destroying or inhibiting growth of unwanted cells or tissues
|
|
US5346981A
(en)
|
1993-01-13 |
1994-09-13 |
Miles Inc. |
Radiopaque polyurethanes
|
|
KR100361933B1
(ko)
|
1993-09-08 |
2003-02-14 |
라 졸라 파마슈티칼 컴파니 |
화학적으로정의된비중합성결합가플랫폼분자및그것의콘주게이트
|
|
US5599796A
(en)
|
1993-12-02 |
1997-02-04 |
Emory University |
Treatment of urogenital cancer with boron neutron capture therapy
|
|
US5627053A
(en)
|
1994-03-29 |
1997-05-06 |
Ribozyme Pharmaceuticals, Inc. |
2'deoxy-2'-alkylnucleotide containing nucleic acid
|
|
US5736557A
(en)
|
1994-06-17 |
1998-04-07 |
Hoffman-La Roche, Inc. |
N,N-bis (quinolin-4-yl)-diamine derivatives, their preparation and their use as antimalarials
|
|
US5716824A
(en)
|
1995-04-20 |
1998-02-10 |
Ribozyme Pharmaceuticals, Inc. |
2'-O-alkylthioalkyl and 2-C-alkylthioalkyl-containing enzymatic nucleic acids (ribozymes)
|
|
US5939045A
(en)
|
1994-12-22 |
1999-08-17 |
Nissan Chemical Industries, Ltd. |
Organic bismuth derivatives for X-ray imaging
|
|
US5700825A
(en)
|
1995-03-31 |
1997-12-23 |
Florida State University |
Radiosensitizing diamines and their pharmaceutical preparations
|
|
US5889136A
(en)
|
1995-06-09 |
1999-03-30 |
The Regents Of The University Of Colorado |
Orthoester protecting groups in RNA synthesis
|
|
DE69637256T2
(de)
|
1996-01-16 |
2008-06-19 |
Sirna Therapeutics, Inc., Boulder |
Synthese von Methoxynukleoside und enzymatische Nukleisäure Moleküle
|
|
ATE279947T1
(de)
|
1996-03-18 |
2004-11-15 |
Univ Texas |
Immunglobulinähnliche domäne mit erhöhten halbwertszeiten
|
|
US5898031A
(en)
|
1996-06-06 |
1999-04-27 |
Isis Pharmaceuticals, Inc. |
Oligoribonucleotides for cleaving RNA
|
|
US9096636B2
(en)
|
1996-06-06 |
2015-08-04 |
Isis Pharmaceuticals, Inc. |
Chimeric oligomeric compounds and their use in gene modulation
|
|
US5849902A
(en)
|
1996-09-26 |
1998-12-15 |
Oligos Etc. Inc. |
Three component chimeric antisense oligonucleotides
|
|
CA2274587A1
(en)
|
1996-12-10 |
1998-06-18 |
Genetrace Systems Inc. |
Releasable nonvolatile mass-label molecules
|
|
US20030073207A1
(en)
|
1997-01-31 |
2003-04-17 |
Saghir Akhtar |
Enzymatic nucleic acid treatment of diseases or conditions related to levels of epidermal growth factor receptors
|
|
US6506559B1
(en)
|
1997-12-23 |
2003-01-14 |
Carnegie Institute Of Washington |
Genetic inhibition by double-stranded RNA
|
|
US6111086A
(en)
|
1998-02-27 |
2000-08-29 |
Scaringe; Stephen A. |
Orthoester protecting groups
|
|
US6528624B1
(en)
|
1998-04-02 |
2003-03-04 |
Genentech, Inc. |
Polypeptide variants
|
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
|
IL138608A0
(en)
|
1998-04-02 |
2001-10-31 |
Genentech Inc |
Antibody variants and fragments thereof
|
|
WO1999054459A2
(en)
|
1998-04-20 |
1999-10-28 |
Ribozyme Pharmaceuticals, Inc. |
Nucleic acid molecules with novel chemical compositions capable of modulating gene expression
|
|
GB9816575D0
(en)
|
1998-07-31 |
1998-09-30 |
Zeneca Ltd |
Novel compounds
|
|
PT1109812E
(pt)
|
1998-08-27 |
2005-09-30 |
Spirogen Ltd |
Pirrolobenzodiazepinas
|
|
GB9818731D0
(en)
|
1998-08-27 |
1998-10-21 |
Univ Portsmouth |
Compounds
|
|
GB9818730D0
(en)
|
1998-08-27 |
1998-10-21 |
Univ Portsmouth |
Collections of compounds
|
|
DE19956568A1
(de)
|
1999-01-30 |
2000-08-17 |
Roland Kreutzer |
Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
|
|
US6849272B1
(en)
|
1999-04-21 |
2005-02-01 |
Massachusetts Institute Of Technology |
Endosomolytic agents and cell delivery systems
|
|
DE10160151A1
(de)
|
2001-01-09 |
2003-06-26 |
Ribopharma Ag |
Verfahren zur Hemmung der Expression eines vorgegebenen Zielgens
|
|
DE10100586C1
(de)
|
2001-01-09 |
2002-04-11 |
Ribopharma Ag |
Verfahren zur Hemmung der Expression eines Ziegens
|
|
US7829693B2
(en)
|
1999-11-24 |
2010-11-09 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of a target gene
|
|
CA2328356A1
(en)
|
1999-12-22 |
2001-06-22 |
Itty Atcravi |
Recreational vehicles
|
|
ES2274823T3
(es)
|
1999-12-29 |
2007-06-01 |
Immunogen, Inc. |
Agentes cototoxicos que comprenden doxorrubicinas y daunorrubicinas y su utilizacion terapeutica.
|
|
US8202979B2
(en)
|
2002-02-20 |
2012-06-19 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid
|
|
US7833992B2
(en)
|
2001-05-18 |
2010-11-16 |
Merck Sharpe & Dohme |
Conjugates and compositions for cellular delivery
|
|
US8273866B2
(en)
|
2002-02-20 |
2012-09-25 |
Merck Sharp & Dohme Corp. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SINA)
|
|
BRPI0117338B1
(pt)
|
2000-03-30 |
2016-06-21 |
Massachusetts Inst Technology |
método para produzir células animais nocauteadas in vitro e método para produzir uma célula nocauteada
|
|
ATE450621T2
(de)
|
2000-03-30 |
2009-12-15 |
Whitehead Biomedical Inst |
Mediatoren von rns-interferenz, die rns- sequenzspezifisch sind
|
|
WO2001083740A2
(en)
|
2000-05-04 |
2001-11-08 |
Avi Biopharma, Inc. |
Splice-region antisense composition and method
|
|
KR100872437B1
(ko)
|
2000-12-01 |
2008-12-05 |
막스-플랑크-게젤샤프트 츄어 푀르더룽 데어 비쎈샤프텐 에.파우. |
Ｒｎａ 간섭을 매개하는 작은 ｒｎａ 분자
|
|
US8546143B2
(en)
|
2001-01-09 |
2013-10-01 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of a target gene
|
|
US6884869B2
(en)
|
2001-04-30 |
2005-04-26 |
Seattle Genetics, Inc. |
Pentapeptide compounds and uses related thereto
|
|
DE10133858A1
(de)
|
2001-07-12 |
2003-02-06 |
Aventis Pharma Gmbh |
Synthetische doppelsträngige Oligonucleotide zur gezielten Hemmung der Genexpression
|
|
MXPA05000511A
(es)
|
2001-07-12 |
2005-09-30 |
Jefferson Foote |
Anticuepros super humanizados.
|
|
US6942972B2
(en)
|
2001-10-24 |
2005-09-13 |
Beckman Coulter, Inc. |
Efficient synthesis of protein-oligonucleotide conjugates
|
|
US6716821B2
(en)
|
2001-12-21 |
2004-04-06 |
Immunogen Inc. |
Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same
|
|
US20060009409A1
(en)
|
2002-02-01 |
2006-01-12 |
Woolf Tod M |
Double-stranded oligonucleotides
|
|
AU2003207708A1
(en)
|
2002-02-20 |
2003-09-09 |
Sirna Therapeutics, Inc. |
Rna interference mediated inhibition of map kinase genes
|
|
US9181551B2
(en)
|
2002-02-20 |
2015-11-10 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
|
|
US9657294B2
(en)
|
2002-02-20 |
2017-05-23 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
|
|
US20040023220A1
(en)
|
2002-07-23 |
2004-02-05 |
Lawrence Greenfield |
Integrated method for PCR cleanup and oligonucleotide removal
|
|
ES2544527T3
(es)
|
2002-07-31 |
2015-09-01 |
Seattle Genetics, Inc. |
Conjugados de fármacos y su uso para tratar el cáncer, una enfermedad autoinmune o una enfermedad infecciosa
|
|
ES2280826T5
(es)
|
2002-08-05 |
2017-08-03 |
Silence Therapeutics Gmbh |
Nuevas formas adicionales de moléculas de ARN de interferencia
|
|
US7923547B2
(en)
|
2002-09-05 |
2011-04-12 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
|
|
JP2006507841A
(ja)
|
2002-11-14 |
2006-03-09 |
ダーマコン， インコーポレイテッド |
機能的ｓｉＲＮＡおよび超機能的ｓｉＲＮＡ
|
|
WO2006006948A2
(en)
|
2002-11-14 |
2006-01-19 |
Dharmacon, Inc. |
METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
|
|
US7250496B2
(en)
|
2002-11-14 |
2007-07-31 |
Rosetta Genomics Ltd. |
Bioinformatically detectable group of novel regulatory genes and uses thereof
|
|
US8084582B2
(en)
|
2003-03-03 |
2011-12-27 |
Xencor, Inc. |
Optimized anti-CD20 monoclonal antibodies having Fc variants
|
|
WO2004090105A2
(en)
|
2003-04-02 |
2004-10-21 |
Dharmacon, Inc. |
Modified polynucleotides for use in rna interference
|
|
WO2004100987A2
(en)
|
2003-05-06 |
2004-11-25 |
Regeneron Pharmaceuticals, Inc. |
Methods of using il-1 antagonists to treat neointimal hyperplasia
|
|
US7276497B2
(en)
|
2003-05-20 |
2007-10-02 |
Immunogen Inc. |
Cytotoxic agents comprising new maytansinoids
|
|
ES2712695T3
(es)
|
2003-06-02 |
2019-05-14 |
Univ Massachusetts |
Métodos y composiciones para controlar la eficacia de la silenciación del ARN
|
|
AU2004252442B2
(en)
|
2003-06-02 |
2010-04-08 |
University Of Massachusetts |
Methods and compositions for enhancing the efficacy and specificity of FNAi
|
|
US7750144B2
(en)
|
2003-06-02 |
2010-07-06 |
University Of Massachusetts |
Methods and compositions for enhancing the efficacy and specificity of RNA silencing
|
|
WO2005014782A2
(en)
|
2003-06-13 |
2005-02-17 |
Alnylam Europe Ag., |
Double-stranded ribonucleic acid with increased effectiveness in an organism
|
|
GB0416511D0
(en)
|
2003-10-22 |
2004-08-25 |
Spirogen Ltd |
Pyrrolobenzodiazepines
|
|
US8133733B2
(en)
|
2003-10-24 |
2012-03-13 |
Gencia Corporation |
Nonviral vectors for delivering polynucleotides to target tissues
|
|
EP3434275A1
(en)
|
2003-11-06 |
2019-01-30 |
Seattle Genetics, Inc. |
Assay for cancer cells based on the use of auristatin conjugates with antibodies
|
|
US8389710B2
(en)
|
2004-02-27 |
2013-03-05 |
Operational Technologies Corporation |
Therapeutic nucleic acid-3′-conjugates
|
|
EP1723152B1
(en)
|
2004-03-09 |
2015-02-11 |
Spirogen Sàrl |
Pyrrolobenzodiazepines
|
|
US8084599B2
(en)
|
2004-03-15 |
2011-12-27 |
City Of Hope |
Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
|
|
KR101147147B1
(ko)
|
2004-04-01 |
2012-05-25 |
머크 샤프 앤드 돔 코포레이션 |
Ｒｎａ 간섭의 오프 타겟 효과 감소를 위한 변형된폴리뉴클레오타이드
|
|
CA2568013C
(en)
|
2004-05-27 |
2015-11-24 |
Alnylam Pharmaceuticals, Inc. |
Nuclease resistant double-stranded ribonucleic acid
|
|
PL1766010T3
(pl)
|
2004-06-28 |
2011-07-29 |
Univ Western Australia |
Antysensowne oligonukleotydy do indukcji pominięcia egzonu i sposoby ich zastosowania
|
|
JP2008519863A
(ja)
|
2004-11-12 |
2008-06-12 |
シアトル ジェネティクス インコーポレイティッド |
Ｎ末端にアミノ安息香酸単位を有するオーリスタチン
|
|
US7429482B2
(en)
|
2005-01-13 |
2008-09-30 |
United States Of America As Represented By The Department Of Veterans Affairs |
Screening tools for discovery of novel anabolic agents
|
|
EP1879901B1
(en)
|
2005-04-21 |
2009-12-23 |
Spirogen Limited |
Pyrrolobenzodiazepines
|
|
CA2610027A1
(en)
|
2005-05-26 |
2006-11-30 |
Ensemble Discovery Corporation |
Biodetection by nucleic acid-templated chemistry
|
|
WO2007008848A2
(en)
|
2005-07-07 |
2007-01-18 |
Seattle Genetics, Inc. |
Monomethylvaline compounds having phenylalanine carboxy modifications at the c-terminus
|
|
CN101287835A
(zh)
|
2005-08-17 |
2008-10-15 |
株式会社百奥尼 |
用于siRNA细胞内输送的siRNA-亲水性聚合物结合物及其方法
|
|
WO2007028065A2
(en)
|
2005-08-30 |
2007-03-08 |
Isis Pharmaceuticals, Inc. |
Chimeric oligomeric compounds for modulation of splicing
|
|
ATE527262T1
(de)
|
2006-01-25 |
2011-10-15 |
Sanofi Sa |
Neue tomaymycin derivate enhaltende zytotoxische mittel
|
|
US7750116B1
(en)
|
2006-02-18 |
2010-07-06 |
Seattle Genetics, Inc. |
Antibody drug conjugate metabolites
|
|
ES2645410T3
(es)
|
2006-05-10 |
2017-12-05 |
Sarepta Therapeutics, Inc. |
Análogos de oligonucleótidos que tienen enlaces intersubunitarios catiónicos
|
|
EP1857548A1
(en)
|
2006-05-19 |
2007-11-21 |
Academisch Ziekenhuis Leiden |
Means and method for inducing exon-skipping
|
|
US8598333B2
(en)
|
2006-05-26 |
2013-12-03 |
Alnylam Pharmaceuticals, Inc. |
SiRNA silencing of genes expressed in cancer
|
|
US7521232B2
(en)
|
2006-05-31 |
2009-04-21 |
Icx Nomadics, Inc. |
Emissive species for clinical imaging
|
|
SG173364A1
(en)
|
2006-07-10 |
2011-08-29 |
Biogen Idec Inc |
Compositions and methods for inhibiting growth of smad4-deficient cancers
|
|
JP6047270B2
(ja)
|
2006-08-11 |
2016-12-21 |
バイオマリン テクノロジーズ ベー．フェー． |
Ｄｎａリピートの不安定性に関連した遺伝的障害を治療するための方法及び手段
|
|
BRPI0715375A2
(pt)
|
2006-08-18 |
2013-06-18 |
Hoffmann La Roche |
policonjugados para distribuiÇço in vivo de polinucleotÍdeos
|
|
EP2532673A3
(en)
|
2007-05-10 |
2014-01-08 |
R & D Biopharmaceuticals Gmbh |
Tubulysine derivatives
|
|
SI2019104T1
(sl)
|
2007-07-19 |
2013-12-31 |
Sanofi |
Citotoksična sredstva, ki obsegajo nove tomaimicinske derivate, in njihova terapevtska uporaba
|
|
EP2193140B1
(en)
|
2007-08-27 |
2016-11-02 |
1Globe Health Institute LLC |
Compositions of asymmetric interfering rna and uses thereof
|
|
EP2190995A2
(en)
|
2007-09-18 |
2010-06-02 |
Intradigm Corporation |
Compositions comprising k-ras sirna and methods of use
|
|
CN101849008A
(zh)
|
2007-09-19 |
2010-09-29 |
应用生物系统有限公司 |
用于减少RNAi中的脱靶表型效应的siRNA的不依赖于序列的修饰形式和其稳定形式
|
|
EP2203173B1
(en)
|
2007-10-26 |
2015-12-23 |
Academisch Ziekenhuis Leiden |
Means and methods for counteracting muscle disorders
|
|
WO2009099991A2
(en)
|
2008-01-31 |
2009-08-13 |
The Brigham And Women's Hospital, Inc. |
Treatment of cancer
|
|
US20110065774A1
(en)
|
2008-01-31 |
2011-03-17 |
Alnylam Pharmaceuticals |
Chemically modified oligonucleotides and uses thereof
|
|
CA2712224C
(en)
|
2008-02-01 |
2016-03-08 |
Ascendis Pharma As |
Prodrug comprising a drug linker conjugate
|
|
EP2247729B1
(en)
|
2008-02-11 |
2019-05-01 |
Phio Pharmaceuticals Corp. |
Modified rnai polynucleotides and uses thereof
|
|
EP2265283B1
(en)
|
2008-03-18 |
2014-09-03 |
Seattle Genetics, Inc. |
Auristatin drug linker conjugates
|
|
EP3604533A1
(en)
|
2008-04-11 |
2020-02-05 |
Arbutus Biopharma Corporation |
Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components
|
|
CA2720363A1
(en)
|
2008-04-15 |
2009-10-22 |
Bira Arya |
Compositions and methods for delivering inhibitory oligonucleotides
|
|
EP2119783A1
(en)
|
2008-05-14 |
2009-11-18 |
Prosensa Technologies B.V. |
Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means
|
|
US20110130346A1
(en)
|
2008-05-30 |
2011-06-02 |
Isis Innovation Limited |
Peptide conjugates for delvery of biologically active compounds
|
|
GB0813432D0
(en)
|
2008-07-22 |
2008-08-27 |
Spirogen Ltd |
Pyrrolobenzodiazepines
|
|
WO2010017544A2
(en)
|
2008-08-08 |
2010-02-11 |
Genisphere, Inc. |
Long-acting dna dendrimers and methods thereof
|
|
CN102123698B
(zh)
|
2008-08-13 |
2016-06-22 |
加利福尼亚技术学院 |
载体纳米颗粒和相关的组合物、方法和系统
|
|
EP3208337A1
(en)
|
2008-09-02 |
2017-08-23 |
Alnylam Pharmaceuticals, Inc. |
Compositions for combined inhibition of mutant egfr and il-6 expression
|
|
US8084601B2
(en)
|
2008-09-11 |
2011-12-27 |
Royal Holloway And Bedford New College Royal Holloway, University Of London |
Oligomers
|
|
EP2340309A2
(en)
|
2008-09-22 |
2011-07-06 |
Rxi Pharmaceuticals Corporation |
Neutral nanotransporters
|
|
CN105779453A
(zh)
|
2008-10-24 |
2016-07-20 |
萨雷普塔治疗公司 |
用于dmd的多外显子跳跃组合物
|
|
PT2344637E
(pt)
|
2008-10-27 |
2015-03-23 |
Academisch Ziekenhuis Leiden |
Métodos e meios para o salto eficiente do exão 45 no pré-mrna de distrofia muscular de duchenne
|
|
SG171914A1
(en)
|
2008-12-02 |
2011-07-28 |
Chiralgen Ltd |
Method for the synthesis of phosphorus atom modified nucleic acids
|
|
CN102365021B
(zh)
|
2009-02-05 |
2015-07-15 |
伊缪诺金公司 |
新型苯并二氮杂*衍生物
|
|
WO2010093788A2
(en)
|
2009-02-11 |
2010-08-19 |
Dicerna Pharmaceuticals, Inc. |
Multiplex dicer substrate rna interference molecules having joining sequences
|
|
US8481698B2
(en)
|
2009-03-19 |
2013-07-09 |
The President And Fellows Of Harvard College |
Parallel proximity ligation event analysis
|
|
WO2010115033A2
(en)
|
2009-04-02 |
2010-10-07 |
Regents Of The University Of Minnesota |
Nucleotide repeat expansion-associated polypeptides and uses thereof
|
|
EP2421971B1
(en)
|
2009-04-24 |
2016-07-06 |
BioMarin Technologies B.V. |
Oligonucleotide comprising an inosine for treating dmd
|
|
JP2012526130A
(ja)
|
2009-05-05 |
2012-10-25 |
アルテルムネ テクフノロジエス，エルエルシー |
化学的にプログラム可能な免疫
|
|
PT2437785E
(pt)
|
2009-06-04 |
2015-04-20 |
Novartis Ag |
Método de identificação de sítios para conjugação de igg
|
|
US20110269665A1
(en)
|
2009-06-26 |
2011-11-03 |
Avi Biopharma, Inc. |
Compound and method for treating myotonic dystrophy
|
|
SG177560A1
(en)
|
2009-07-06 |
2012-03-29 |
Hoffmann La Roche |
Bi-specific digoxigenin binding antibodies
|
|
JP2012533587A
(ja)
|
2009-07-22 |
2012-12-27 |
セニックス バイオサイエンス ゲーエムベーハー |
自然に存在する細胞内輸送経路を介して化合物を送達するための送達システム及びコンジュゲート
|
|
IT1394860B1
(it)
|
2009-07-22 |
2012-07-20 |
Kemotech S R L |
Composti farmaceutici
|
|
EP2473607A2
(en)
|
2009-08-31 |
2012-07-11 |
INSERM - Institut National de la Santé et de la Recherche Médicale |
Exon skipping therapy for functional amelioration of semi functional dystrophin in becker and duchenne muscular dystrophy
|
|
AU2010303415B2
(en)
|
2009-10-07 |
2015-02-19 |
Macrogenics, Inc. |
Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use
|
|
BR122023023194A2
(pt)
|
2009-11-12 |
2023-12-26 |
The University Of Western Australia |
Oligonucleotídeo antissentido, composição e respectivo uso
|
|
EP2534174A4
(en)
|
2010-02-12 |
2015-02-25 |
Solulink Inc |
Preparation and / or purification of oligonucleotide conjugates
|
|
ES2623057T3
(es)
|
2010-04-15 |
2017-07-10 |
Medimmune Limited |
Pirrolobenzodiazepinas usadas para tratar enfermedades proliferativas
|
|
JP5870400B2
(ja)
|
2010-04-15 |
2016-03-01 |
シアトル ジェネティクス，インコーポレーテッド |
標的化ピロロベンゾジアゼピンコンジュゲート
|
|
EP2601204B1
(en)
|
2010-04-28 |
2016-09-07 |
Ionis Pharmaceuticals, Inc. |
Modified nucleosides and oligomeric compounds prepared therefrom
|
|
KR102182663B1
(ko)
|
2010-05-28 |
2020-11-25 |
사렙타 쎄러퓨틱스, 인코퍼레이티드 |
변형된 서브유니트간 결합 및/또는 말단 그룹을 갖는 올리고뉴클레오타이드 유사체
|
|
IT1400425B1
(it)
|
2010-06-08 |
2013-05-31 |
Amsterdam Molecular Therapeutics Bv |
Modified snrnas for use in therapy.
|
|
AU2011263642B2
(en)
|
2010-06-11 |
2014-09-04 |
Isarna Therapeutics Gmbh |
Method for selective oligonucleotide modification
|
|
EP2409983A1
(en)
|
2010-07-19 |
2012-01-25 |
Leibniz-Institut für Pflanzenbiochemie (IPB) |
Tubulysin analogues
|
|
EP3489360A3
(en)
|
2010-07-19 |
2019-08-28 |
Ionis Pharmaceuticals, Inc. |
Modulation of nuclear-retained rna
|
|
EP2606152B2
(en)
*
|
2010-08-18 |
2025-03-12 |
Fred Hutchinson Cancer Center |
Methods for determining the presence or risk of developing facioscapulohumeral dystrophy (fshd)
|
|
EP2606072A4
(en)
|
2010-08-19 |
2016-04-20 |
Peg Biosciences Inc |
SYNERGISTIC BIOMOLECULAR POLYMER CONJUGATES
|
|
EP2426203B1
(en)
*
|
2010-09-02 |
2016-07-13 |
Université de Mons |
Agents useful in treating facioscapulohumeral muscular dystrophy
|
|
EP3766975A1
(en)
|
2010-10-29 |
2021-01-20 |
Sirna Therapeutics, Inc. |
Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina)
|
|
JP2013542958A
(ja)
|
2010-11-03 |
2013-11-28 |
イミュノジェン・インコーポレーテッド |
アンサマイトシン誘導体を含む細胞傷害性剤
|
|
US8501930B2
(en)
|
2010-12-17 |
2013-08-06 |
Arrowhead Madison Inc. |
Peptide-based in vivo siRNA delivery system
|
|
NZ611656A
(en)
|
2010-12-29 |
2014-10-31 |
Arrowhead Res Corp |
In vivo polynucleotide delivery conjugates having enzyme sensitive linkages
|
|
CA2826836A1
(en)
|
2011-02-08 |
2012-08-16 |
The Charlotte-Mecklenburg Hospital Authority D/B/A Carolinas Medical Center |
Antisense oligonucleotides
|
|
MX348071B
(es)
|
2011-03-16 |
2017-05-26 |
Amgen Inc |
Variantes de fc.
|
|
US9045750B2
(en)
|
2011-03-18 |
2015-06-02 |
Yuelong Ma |
Humanized lewis-Y specific antibody-based delivery of dicer substrate siRNA (D-siRNA) against STAT3
|
|
ES2692268T5
(en)
|
2011-03-29 |
2025-02-26 |
Roche Glycart Ag |
Antibody fc variants
|
|
MX350954B
(es)
|
2011-06-21 |
2017-09-26 |
Immunogen Inc |
Derivados de maitansinoides novedosos con enlazador de peptido y conjugados de estos.
|
|
EP2732035A2
(en)
|
2011-07-15 |
2014-05-21 |
Sarepta Therapeutics, Inc. |
Methods and compositions for manipulating translation of protein isoforms from alternative initiation start sites
|
|
US9605019B2
(en)
|
2011-07-19 |
2017-03-28 |
Wave Life Sciences Ltd. |
Methods for the synthesis of functionalized nucleic acids
|
|
AU2012286994B2
(en)
*
|
2011-07-25 |
2017-08-10 |
Nationwide Children's Hospital, Inc. |
Recombinant virus products and methods for inhibition of expression of DUX4
|
|
EP3640332A1
(en)
|
2011-08-29 |
2020-04-22 |
Ionis Pharmaceuticals, Inc. |
Oligomer-conjugate complexes and their use
|
|
US9526798B2
(en)
|
2011-10-14 |
2016-12-27 |
Seattle Genetics, Inc. |
Pyrrolobenzodiazepines and targeted conjugates
|
|
US9593141B2
(en)
|
2011-11-09 |
2017-03-14 |
President And Fellows Of Harvard College |
Lin28/let-7 crystal structures, purification protocols, and molecular probes suitable for screening assays and therapeutics
|
|
IL303831A
(en)
|
2011-11-18 |
2023-08-01 |
Alnylam Pharmaceuticals Inc |
Adapted RNAI factors
|
|
AU2012348017A1
(en)
|
2011-12-05 |
2014-07-03 |
Igenica Biotherapeutics, Inc. |
Antibody-drug conjugates and related compounds, compositions, and methods
|
|
US20130177579A1
(en)
|
2012-01-06 |
2013-07-11 |
Bioalliance C.V. |
Anti-transferrin receptor antibodies and methods using same
|
|
US10010623B2
(en)
|
2012-02-16 |
2018-07-03 |
Ucl Business Plc |
Lysosome-cleavable linker
|
|
BR112014020697B1
(pt)
|
2012-02-24 |
2024-01-09 |
Alteogen Inc |
Anticorpo modificado compreendendo um motivo contendo cisteína na terminação do anticorpo, conjugado anticorpo-droga modificado compreendendo uma droga ligada ao anticorpo modificado e método de produção do mesmo
|
|
EP3736333A1
(en)
|
2012-05-02 |
2020-11-11 |
Arrowhead Pharmaceuticals, Inc. |
Organic compositions to treat kras-related diseases
|
|
AR090905A1
(es)
|
2012-05-02 |
2014-12-17 |
Merck Sharp & Dohme |
Conjugados que contienen tetragalnac y peptidos y procedimientos para la administracion de oligonucleotidos, composicion farmaceutica
|
|
EP3925627A1
(en)
|
2012-05-15 |
2021-12-22 |
Concortis Biosystems, Corp |
Drug-conjugates and uses thereof
|
|
US9504756B2
(en)
|
2012-05-15 |
2016-11-29 |
Seattle Genetics, Inc. |
Self-stabilizing linker conjugates
|
|
CN112007045B
(zh)
|
2012-07-13 |
2026-01-06 |
波涛生命科学有限公司 |
手性控制
|
|
EP2885313A4
(en)
|
2012-08-20 |
2016-03-09 |
Univ California |
POLYNUCLEOTIDES WITH BIOREVERSIBLE GROUPS
|
|
KR102058381B1
(ko)
|
2012-08-24 |
2019-12-24 |
강원대학교산학협력단 |
인간 ｌ１ｃａｍ에 대한 인간화 항체 및 그의 제조 방법
|
|
ES2738310T3
(es)
|
2012-10-12 |
2020-01-21 |
Medimmune Ltd |
Pirrolobenzodiazepinas y conjugados de las mismas
|
|
SG10201804331TA
(en)
|
2012-11-15 |
2018-07-30 |
Roche Innovation Ct Copenhagen As |
Oligonucleotide conjugates
|
|
AU2012395148B2
(en)
|
2012-11-24 |
2016-10-27 |
Hangzhou Dac Biotech Co., Ltd. |
Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules
|
|
KR20150119848A
(ko)
|
2012-12-21 |
2015-10-26 |
바이오얼라이언스 씨.브이. |
친수성 자기-희생 링커 및 그것의 포합체
|
|
US9481905B2
(en)
|
2013-02-19 |
2016-11-01 |
Orizhan Bioscience Limited |
Method of using neutrilized DNA (N-DNA) as surface probe for high throughput detection platform
|
|
AU2014244245C1
(en)
|
2013-03-13 |
2018-04-19 |
Genentech, Inc. |
Pyrrolobenzodiazepines and conjugates thereof
|
|
EA202090946A3
(ru)
|
2013-03-14 |
2021-07-30 |
Сарепта Терапьютикс, Инк. |
Композиции, обеспечивающие пропускание экзонов, для лечения мышечной дистрофии
|
|
EP2777714A1
(en)
|
2013-03-15 |
2014-09-17 |
NBE-Therapeutics LLC |
Method of producing an immunoligand/payload conjugate by means of a sequence-specific transpeptidase enzyme
|
|
NZ631289A
(en)
|
2013-03-15 |
2017-08-25 |
Sarepta Therapeutics Inc |
Improved compositions for treating muscular dystrophy
|
|
EP3964237B1
(en)
|
2013-03-15 |
2026-02-18 |
Regeneron Pharmaceuticals, Inc. |
Biologically active molecules, conjugates thereof, and therapeutic uses
|
|
CA2908096C
(en)
|
2013-03-27 |
2022-05-03 |
Isarna Therapeutics Gmbh |
Modified tgf-beta oligonucleotides
|
|
US9295731B2
(en)
|
2013-04-01 |
2016-03-29 |
Mark Quang Nguyen |
Cleavable drug conjugates, compositions thereof and methods of use
|
|
US9861574B2
(en)
|
2013-04-09 |
2018-01-09 |
Duke University |
2-fluoro-modified RNAs as immunostimulators
|
|
GB2529356B
(en)
|
2013-04-28 |
2020-12-23 |
Genequantum Healthcare Co Ltd |
Novel linkers, coupling intermediates, conjugates, preparation method and application thereof
|
|
EA038367B1
(ru)
|
2013-05-20 |
2021-08-16 |
Дженентек, Инк. |
АНТИТЕЛА ПРОТИВ РЕЦЕПТОРА ТРАНСФЕРРИНА (TfR) И СПОСОБЫ ИХ ИСПОЛЬЗОВАНИЯ
|
|
RU2655439C2
(ru)
|
2013-05-31 |
2018-05-28 |
Займворкс Инк. |
Гетеромультимеры с уменьшенной или подавленной эффекторной функцией
|
|
WO2014197854A1
(en)
|
2013-06-06 |
2014-12-11 |
Igenica Biotherapeutics, Inc. |
Novel linkers for antibody-drug conjugates and related compounds, compositions, and methods of use
|
|
US20140363454A1
(en)
|
2013-06-06 |
2014-12-11 |
Igenica Biotherapeutics, Inc. |
Antibody-Drug Conjugates, Compositions and Methods of Use
|
|
TW201536329A
(zh)
|
2013-08-09 |
2015-10-01 |
Isis Pharmaceuticals Inc |
用於調節失養性肌強直蛋白質激酶(dmpk)表現之化合物及方法
|
|
EP2845607A1
(en)
|
2013-09-09 |
2015-03-11 |
University of Vienna |
Antisense oligonucleotides with improved pharmacokinetic properties
|
|
WO2015038426A1
(en)
|
2013-09-13 |
2015-03-19 |
Asana Biosciences, Llc |
Self-immolative linkers containing mandelic acid derivatives, drug-ligand conjugates for targeted therapies and uses thereof
|
|
AU2014337555C1
(en)
|
2013-10-15 |
2021-01-28 |
Seagen Inc. |
PEGylated drug-linkers for improved Ligand-Drug Conjugate pharmacokinetics
|
|
EP3057610B1
(en)
|
2013-10-15 |
2021-09-22 |
Sorrento Therapeutics, Inc. |
Drug-conjugates with a targeting molecule and two different drugs
|
|
EP3610884B1
(en)
|
2013-11-06 |
2021-08-18 |
Merck Sharp & Dohme Corp. |
Peptide containing conjugates for dual molecular delivery of oligonucleotides
|
|
WO2015084846A1
(en)
|
2013-12-02 |
2015-06-11 |
Brandeis University |
High temperature selection of nucleotide-supported carbohydrate vaccines and resulting glycosylated oligonucleotides
|
|
KR102423317B1
(ko)
|
2014-01-16 |
2022-07-22 |
웨이브 라이프 사이언시스 리미티드 |
키랄 디자인
|
|
JP2017505623A
(ja)
|
2014-01-30 |
2017-02-23 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
生物切断性コンジュゲートを有するポリオリゴマー化合物
|
|
AU2015277924B2
(en)
|
2014-06-17 |
2021-02-25 |
National Center Of Neurology And Psychiatry |
Antisense nucleic acids
|
|
TWI695011B
(zh)
|
2014-06-18 |
2020-06-01 |
美商梅爾莎納醫療公司 |
抗ｈｅｒ２表位之單株抗體及其使用之方法
|
|
WO2015200223A1
(en)
|
2014-06-23 |
2015-12-30 |
Monsanto Technology Llc |
Compositions and methods for regulating gene expression via rna interference
|
|
IL316808A
(en)
|
2014-08-20 |
2025-01-01 |
Alnylam Pharmaceuticals Inc |
Modified double-stranded RNA materials and their uses
|
|
JP6779876B2
(ja)
|
2014-11-19 |
2020-11-04 |
ジェネンテック， インコーポレイテッド |
抗トランスフェリン受容体抗体及びその使用方法
|
|
WO2016115490A1
(en)
|
2015-01-16 |
2016-07-21 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulation of dux4
|
|
US20180305689A1
(en)
|
2015-04-22 |
2018-10-25 |
Mina Therapeutics Limited |
Sarna compositions and methods of use
|
|
ES2905181T3
(es)
|
2015-05-01 |
2022-04-07 |
Prec Biosciences Inc |
Deleción precisa de secuencias cromosómicas in vivo
|
|
CN114681621B
(zh)
|
2015-05-19 |
2024-08-06 |
萨勒普塔医疗公司 |
肽寡核苷酸缀合物
|
|
CR20210429A
(es)
|
2015-06-24 |
2021-09-24 |
Hoffmann La Roche |
ANTICUERPOS ANTI-RECEPTOR DE TRANSFERRINA CON AFINIDAD DISEÑADA (Divisional 2017-0562)
|
|
US20170009230A1
(en)
*
|
2015-07-08 |
2017-01-12 |
Idera Pharmaceuticals, Inc. |
Compositions for inhibiting dux4 gene expression and uses thereof
|
|
JP6749589B2
(ja)
*
|
2015-07-31 |
2020-09-02 |
国立大学法人北海道大学 |
抗Ｅｖａ１タンパク質抗体
|
|
JP2019515874A
(ja)
|
2016-03-01 |
2019-06-13 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
改変された細胞死誘導を有するオビヌツズマブ変異体
|
|
KR102775461B1
(ko)
*
|
2016-04-01 |
2025-02-28 |
어비디티 바이오사이언시스 인크. |
핵산-폴리펩타이드 조성물 및 이의 용도
|
|
US20190249173A1
(en)
|
2016-05-04 |
2019-08-15 |
Chandra Vargeese |
Methods and compositions of biologically active agents
|
|
US20190240346A1
(en)
|
2016-06-20 |
2019-08-08 |
Genahead Bio, Inc. |
Antibody-drug conjugate
|
|
WO2018002812A1
(en)
|
2016-06-29 |
2018-01-04 |
Crispr Therapeutics Ag |
Materials and methods for treatment of myotonic dystrophy type 1 (dm1) and other related disorders
|
|
WO2018078134A1
(en)
|
2016-10-28 |
2018-05-03 |
Genethon |
Compositions and methods for the treatment of myotonic dystrophy
|
|
US20190256868A1
(en)
|
2016-10-28 |
2019-08-22 |
Genethon |
Compositions and methods for the treatment of myotonic dystrophy
|
|
KR102645243B1
(ko)
|
2016-11-23 |
2024-03-11 |
알닐람 파마슈티칼스 인코포레이티드 |
표적외 효과가 감소된 변형 rna 작용제
|
|
CN110381980A
(zh)
*
|
2017-01-06 |
2019-10-25 |
艾维迪提生物科学有限责任公司 |
核酸-多肽组合物以及诱导外显子跳读的方法
|
|
JOP20190187A1
(ar)
|
2017-02-03 |
2019-08-01 |
Novartis Ag |
مترافقات عقار جسم مضاد لـ ccr7
|
|
EP3444010B1
(en)
*
|
2017-08-14 |
2020-12-09 |
ScandiEdge Therapeutics AB |
Pklr inhibition in the treatment of nafld and hcc
|
|
MA50269A
(fr)
|
2017-09-22 |
2020-07-29 |
Avidity Biosciences Inc |
Compositions d'acides nucléiques-polypeptides et méthodes d'induction de saut d'exon
|
|
EP3668997A4
(en)
|
2017-10-02 |
2021-05-19 |
Research Institute at Nationwide Children's Hospital |
SYSTEM FOR MIRNA DETARGETING FOR TISSUE-SPECIFIC INTERFERENCE
|
|
US11110180B2
(en)
|
2017-10-04 |
2021-09-07 |
Avidity Biosciences Inc. |
Nucleic acid-polypeptide compositions and uses thereof
|
|
WO2019071144A1
(en)
*
|
2017-10-05 |
2019-04-11 |
Fulcrum Therapeutics, Inc. |
USE OF P38 INHIBITORS TO REDUCE DUX4 EXPRESSION
|
|
CN118638788A
(zh)
*
|
2017-12-06 |
2024-09-13 |
艾维迪提生物科学公司 |
治疗肌萎缩和强直性肌营养不良的组合物和方法
|
|
JP7611825B2
(ja)
*
|
2018-08-02 |
2025-01-10 |
ダイン セラピューティクス，インコーポレーテッド |
ジストロフィン異常症を処置するための筋標的化複合体およびそれらの使用
|
|
US20220378934A1
(en)
*
|
2018-08-02 |
2022-12-01 |
Dyne Therapeutics, Inc. |
Muscle-targeting complexes and uses thereof in treating muscle atrophy
|
|
US20220193250A1
(en)
*
|
2018-08-02 |
2022-06-23 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
|
|
IL319265A
(en)
|
2018-12-21 |
2025-04-01 |
Avidity Biosciences Inc |
Anti-transferrin receptor antibodies and their uses
|
|
AU2019419494B2
(en)
|
2018-12-31 |
2026-03-26 |
Research Institute At Nationwide Children's Hospital |
DUX4 RNA silencing using RNA targeting CRISPR-Cas13b
|
|
BR112021018793A2
(pt)
|
2019-03-29 |
2021-11-23 |
Mitsubishi Tanabe Pharma Corp |
Oligonucleotídeo modificado, composição farmacêutica compreendendo o mesmo composto para modular a expressão de dux4 e uso
|
|
US12006499B2
(en)
|
2019-06-06 |
2024-06-11 |
Avidity Biosciences, Inc. |
Una amidites and uses thereof
|
|
US20230088865A1
(en)
|
2020-01-10 |
2023-03-23 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
|
|
WO2021188390A1
(en)
|
2020-03-19 |
2021-09-23 |
Avidity Biosciences, Inc. |
Compositions and methods of treating facioscapulohumeral muscular dystrophy
|
|
CA3189861A1
(en)
|
2020-09-01 |
2022-03-10 |
Sean Christopher DAUGHERTY |
Dux4 inhibitors and methods of use thereof
|
|
US11638761B2
(en)
|
2021-07-09 |
2023-05-02 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy
|
|
CN117677698A
(zh)
|
2021-07-14 |
2024-03-08 |
米雷楚来股份有限公司 |
用于神经肌肉障碍的寡核苷酸及其组合物
|
|
MX2024003266A
(es)
*
|
2021-09-16 |
2024-04-03 |
Avidity Biosciences Inc |
Composiciones y metodos de tratamiento de la distrofia muscular facioescapulohumeral.
|